Goldman Sachs Group Inc X Biotech Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in X Biotech Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 112,084 shares of XBIT stock, worth $243,222. This represents 0.0% of its overall portfolio holdings.

Number of Shares

112,084

Previous 47,182 137.56%

Holding current value

$243,222

Previous $152,000 118.42%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.56 - $3.36 $166,149 - $218,070	64,902 Added 137.56%	112,084 $332,000
Q1 2025 May 09, 2025	SELL	$2.99 - $4.48 $19,578 - $29,335	-6,548 Reduced 12.19%	47,182 $152,000
Q4 2024 Feb 11, 2025	BUY	$3.8 - $8.25 $50,585 - $109,824	13,312 Added 32.94%	53,730 $212,000
Q3 2024 Nov 14, 2024	BUY	$5.55 - $7.95 $151,248 - $216,653	27,252 Added 206.99%	40,418 $312,000
Q2 2024 Aug 13, 2024	SELL	$4.54 - $9.89 $222,437 - $484,560	-48,995 Reduced 78.82%	13,166 $67,000
Q1 2024 May 15, 2024	BUY	$4.03 - $8.13 $250,508 - $505,368	62,161 New	62,161 $505,000
Q2 2022 May 14, 2024	BUY	$5.13 - $9.2 $51,823 - $92,938	10,102 New	10,102 $57,000
Q2 2022 Aug 15, 2022	SELL	$5.13 - $9.2 $246,881 - $442,749	-48,125 Reduced 82.65%	10,102 $57,000
Q1 2022 May 16, 2022	BUY	$8.64 - $11.71 $144,624 - $196,013	16,739 Added 40.35%	58,227 $503,000
Q4 2021 Feb 14, 2022	SELL	$10.95 - $16.07 $167,195 - $245,372	-15,269 Reduced 26.9%	41,488 $462,000
Q3 2021 Nov 10, 2021	BUY	$12.95 - $18.24 $735,003 - $1.04 Million	56,757 New	56,757 $735,000

Others Institutions Holding XBIT

# of Institutions

Shares Held

4.4M

Call Options Held

Put Options Held

View Full List

About XBiotech Inc.

Ticker XBIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,439,300
Market Cap $66.1M
Description
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical...

More about XBIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc X Biotech Inc. Transaction History